Of course, from a diagnostic or therapeutic perspective, the use of CSF biomarkers or amyloid or tau PET radiotracers will still be important keeping also in mind the recent development of plasma biomarkers which could dramatically change the lines of investigations regarding the diagnosis of neurodegenerative diseases [11, 32]. Here, MAPT is linked to neurodegenerative disease.